Does smoking decrease the response to infliximab in patients with Crohn's disease?
Parsi
Mansour A
MA
Digestive Disease Institute, Cleveland Clinic, Ohio, USA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D012907:Smoking / Q000009:adverse effects*; D013997:Time Factors; D017211:Treatment Failure; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab